Adherence to oral antineoplastic agents by cancer patients: Definition and literature review

European Journal of Cancer Care

Volumn 23, Issue 1, 2014, Pages 22-35

  Bassan, F ^a   Peter, F ^a   Houbre, B ^a   Brennstuhl, M J ^a   Costantini, M ^a   Speyer, E ^a   Tarquinio, C ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Adherence; Cancer; Compliance; Oncology; Oral chemotherapy; Systematic review; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT;

HUMAN; MEDICATION COMPLIANCE; NEOPLASMS; NOMENCLATURE; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION; PSYCHOLOGY;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; HUMANS; MEDICATION ADHERENCE; NEOPLASMS; PATIENT EDUCATION AS TOPIC; TERMINOLOGY AS TOPIC;

EID: 84890972417     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/ecc.12124     Document Type: Article

References (66)

1. Accordino M.K. & Hershman D.L. (2013) Disparities and challenges in adherence to oral antoneoplasctix agents. American Society of Clinical Oncology Educational Book 2013, 271-276.
2. Aisner J. (2007) Overview of the changing paradigm in cancer treatment: oral chemotherapy. American Journal of Health-System Pharmacy 64, 4-7.
3. Ankri J., Le Disert D. & Henrard J.C. (1995) Comportements individuels face aux médicaments. De l'observance thérapeutique à l'expérience de la maladie. Analyse de la littérature. Santé Publique 12, 427-441.
4. Bailey W.C., Richards J.M., Brooks C.M., Soong S.J., Windsor R.A. & Manzella B.A. (1990) A randomized trial to improve self-management practices of adults with asthma. Archives of Internal Medicine 150, 1664-1668.
5. Bedell C.H. (2003) A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clinical Journal of Oncology Nursing 7, 5-9.
6. Besch C.L. (1995) Compliance in clinical trials. AIDS 91, 1-10.
7. Bhattacharya D., Easthall C., Willoughby K.A., Small M. & Watson S. (2012) Capecitabine non-adherence: exploration of magnitude, nature and contributing factors. Journal of Oncology Pharmacy Practice 18, 333-342.
8. Blackwell B. (1973) Patient compliance. The New England Journal of Medicine 2, 249-252.
9. Blackwell B. (1992) Compliance. Psychotherapy and Psychosomatics 58, 161-169.
10. Bond W. & Hussar D.A. (1991) Detection method strategies for improving medication compliance. American Journal of Public Health 48, 1978-1988.
11. Brooks G.M., Richard J.M., Kohler C.L. & Soong S.J. (1996) Assessing adherence to asthma medication and inhaler regimens: a psychometric analysis of adult self report scales. Medical Care 32, 298-307.
12. Campone M., Berton-Rigaud D., Bourbouloux E. & Le Pourhiet A. (2007) Avantages et inconvénients des thérapies orales pour les patients. Eurocancer 2007, 97-100.
13. Caron H.S. (1985) Compliance: the case for objective measurement. Journal of Hypertension 3, 11-17.
14. Cassidy J. (2005) Benefits and drawbacks of the use of oral fluoropyrimides as single-agent therapy in advanced colorectal cancer. Clinical Colorectal Cancer 5, 47-50.
15. Catania C., Didier F., Leon M.E., Sbanotto A., Mariani L., Nolè F., Leida E., Rocca A., De Pas, T. & Goldhirsch A. (2005) Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Research and Treatment 92, 265-272.
16. Cotton S. & Antill J.K. (1984) Noncompliance: medical and psychological aspects. Australian Psychologist 19, 193-204.
17. Cramer J.A. (2004) A systematic review of adherence with medications for diabetes. Diabetes Care 27, 1218-1224.
18. Darkow T., Henk H.J., Thomas S.K., Feng W., Baladi J.F., Goldberg G.A., Hatfield A. & Cortes J. (2007) Treatment interruptions and non-adherence with imatinib and associated healthcare costs. Pharmacoeconomics 25, 483-496.
19. Decker V., Spoelstra S., Miezo E., Bremer R., You M., Given C. & Given B. (2009) A pilot study of an automated voice response system and nursing intervention to monitor adherence to oral chemotherapy agents. Cancer Nursing 32, 20-29.
20. Ebrahim S. (1998) Detection, adherence and control of hypertension for the prevention of stroke: a systematic review. Health Technology Assessment 2 (11), i-iv, 1-78.
21. Faithfull S. & Deery P. (2004) Implementation of capecitabine (Xeloda) into a cancer centre: UK experience. European Journal of Oncology Nursing 8, 54-62.
22. Findlay M., Von Inckwitz G. & Wardley A. (2008) Effective oral chemotherapy for breast cancer: pillars of strength. Annals of Oncology 19, 212-222.
23. Ganesan P., Sagar T.G., Dubashi B., Rajendranath R., Kannan K., Cyriac S. & Nandennavar N. (2011) Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. American Journal of Hematology 86, 471-474.
24. Gebbia V., Bellavia M., Banna G.L., Russo P., Ferraù F., Tralongo P. & Borsellino N. (2013) Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small cell lung cancer. Clinical Lung Cancer 14, 390-398.
25. Geletko S.M., Segarra M., Mayer K.H., Fiore T.C., Bettencourt F.A., Flanigan T.P. & Dudley M.N. (1996) Electronic compliance assessment of antifungal prolaxis for human immunodeficiency virus-infected women. Antimicrobial Agents and Chemotherapy 40, 1338-1341.
26. Given B.A., Spoelstra S.L. & Grant M. (2011) The challenges of oral agents as antineoplastic treatments. Seminars in Oncology Nursing 27, 93-103.
27. Gordis L., Markowitz M. & Lilienfeld A.M. (1969) Why patients don't follow medical advice: a study of children on long-term antistreptococcal prophylaxis. The Journal of Pediatrics 75, 957-968.
28. Gryfe C.I. & Gryfe B.M. (1984) Drug therapy of the aged: the problem of compliance and the roles of physicians and pharmacists. Journal of the American Geriatrics Society 32, 301-307.
29. Hamilton S., Jo H. & Statman M. (1993) Doing well while doing good? The investment performance of socially responsible mutual funds. Financial Analyst Journal 49, 62-66.
30. Haynes R.B., Taylor D.W. & Sackett D.L. (1979) Compliance in Health Care. Johns Hopkins University Press, Baltimore, MD, USA.
31. Holzemer W.L., Corless I.B., Nokes K.M., Turner J.G., Brown M.A., Powell-Cope G.M., Inouye J., Henry S.B., Nicholas P.K. & Portillo C.J. (1999) Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care and STDs 13, 185-197.
32. Institut Européen du Cancer (2005) Opinion des femmes à l'égard de la chimiothérapie par voie orale. Enquête BVA.
33. Kass M.A., Meltzer D.W. & Gordon M.A. (1984) A miniature compliance monitor for ophthalmology. Archives of Ophthalmology 102, 1550-1554.
34. Kass M.A., Meltzer D.W., Gordon M.A., Cooper D. & Goldberg J. (1986) Compliance with topical pilocarpine treatment. American Journal of Ophthalmology 101, 515-523.
35. Khandelwal N., Duncan I., Ahmed T., Rubinstein E. & Pegus C. (2012) Oral chemotherapy program improves adherence and reduces medication wastage and hospital admissions. Journal of the National Comprehensive Cancer Network 10, 618-625.
36. Klein C.E., Kastrissios H., Miller A.A., Hollis D., Yu D., Rosner G.L., Grinblatt D.L., Larson R.A. & Ratain M.J. (2006) Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a cancer and leukemia group B study. Cancer Chemotherapy and Pharmacology 57, 199-206.
37. Kravitz R., Hays R.D., Sherbourne C.D., Dimatteo M.R., Rogers W., Ordway L. & Greenfield S. (1993) Recall of recommendations and adherence to advice among patients with chronic medical conditions. Archives of Internal Medicine 153, 1869-1878.
38. Lebovits A.H., Strain J.J., Schleifer S.J., Tanaka J.S., Bhardwaj S. & Messe M.R. (1990) Patient nonobservance with self-administered chemotherapy. Health Psychology 9, 405-417.
39. Lee C.R., Nicholson P.W., Souhami R.L. & Deshukh A.A. (1992) Patient observance with oral chemotherapy as assessed by a novel electronic technique. Journal of Clinical Oncology 10, 1007-1013.
40. Lee C.R., Nicholson P.W., Souhami R.L., Slevin M.L., Hall M.R. & Deshmukh A.A. (1993) Patient observance with prolonged low-dose oral etoposide for small cell lung cancer. British Journal of Cancer 67, 630-634.
41. Lee C.R., Nicholson P.W., Ledermann J.A. & Rustin G.J. (1996) Patient observance with prolonged oral altretamine treatment in relapsed ovarian cancer. European Journal of Gynaecological Oncology 17, 99-103.
42. Liu G., Franssen E., Fitch M.I. & Warner E. (1997) Patients preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Oncology 15, 110-115.
43. MacIntosh P.W., Pond G.R., Pond B.J., Leung V. & Siu L.L. (2007) A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes. European Journal of Cancer Care 16, 380-386.
44. Mayer E.L., Partridge A.H., Harris L.N., Gelman R.S., Schumer S.T., Burstein H.J. & Winer E.P. (2009) Tolerability of and adherence to combination oral therapy with Gefitinib and Capecitabine in metastatic breast cancer. Breast Cancer Research and Treatment 117, 615-623.
45. Moon J.H., Sohan S.K., Kim S.N., Park S.Y., Yoon S.S., Kim I.H., Kim H.J., Kim Y.K., Min Y.H., Cheong J.W., Kim J.S., Jung C.W. & Kim D.H. (2012) Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. Medical Oncology (Northwood, London, England) 29, 1179-1185.
46. Morisky D.E., Green L.W. & Levine D.M. (1986) Concurrent and predictive validity of a self-report measure of medication adherence. Medical Care 24, 67-74.
47. Myers L.B. & Midence K. (1998) Adherence to Treatment in Medical Conditions. Harwood Academic Publishers, Amsterdam, the Netherlands.
48. Noens L., Van Lierde M.A., De Bock R., Verhoef G., Zachée P., Berneman Z., Martiat P., Mineur P., Van Eygen K., MacDonald K., De Geest S., Albrecht T. & Abraham I. (2009) Prevalence, determinants and outcomes of nonadherence to Imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113, 5401-5411.
49. O'Brien M.K., Petrie K. & Raeburn J. (1992) Adherence to medication regimens: updating a complex medical issue. Medical Care 49, 435-454.
50. O'Neill V.J. & Twelves C.J. (2002) Oral cancer treatment developments in chemotherapy and beyond. British Journal of Cancer 87, 933-937.
51. Osterberg L. & Blaschke T. (2005) Adherence to medication. The New England Journal of Medicine 353, 487-497.
52. Palmieri F.M. & Barton D. (2007) Challenges of oral medications in patients with advanced breast cancer. Seminars in Oncology Nursing 23, 17-22.
53. Partridge A.H., Avorn J., Wang P.S. & Winer E.P. (2002) Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute 94, 652-661.
54. Partridge A.H., Archer L., Kornblith A.B., Gralow J., Grenier D., Perez E., Wolff A.C., Wang X., Kastrissios H., Berry D., Hudis C., Winer E. & Muss H. (2010) Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in GALB 49907: adherence companion study 60104. Journal of Clinical Oncology 28, 2418-2422.
55. Paterson D.L., Swindells S., Mohr J., Brester M., Vergis E.N., Squier C., Wagener M.M. & Singh N. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 133, 21-30.
56. Pfeiffer P., Mortensen J.P., Bjerregaard B., Eckhoff L., Schønnemann K., Sandberg E., Aabo K. & Jakobsen A. (2006) Patient preference for oral or intravenous chemotherapy: a randomized cross-over trial comparing Capecitabine and Nordic Fluorouracil/Leucovorin in patients with colorectal cancer. European Journal of Cancer 42, 2738-2743.
57. Ranchon F., Bouret C., Charpiat B. & Leboucher G. (2009) Sécurisation de l'emploi des chimiothérapies anticancéreuses administrables par voie orale. Le Pharmacien Hospitalier 44, 36-44.
58. Regnier-Denois V., Poirson J., Soum-Pouyalet F. & Chauvin F. (2009) La chimiothérapie par voie orale: représentations et pratiques des oncologues et des patients. Psycho-oncology 3, 168-175.
59. Regnier-Denois V., Poirson J., Nourissat A., Jacquin J.P., Gustalla J.P. & Chauvin F. (2011) Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. European Journal of Cancer Care 20, 520-527.
60. Sadahiro S., Ohki S., Yamaguchi S., Takahashi T., Otani Y., Tsukikawa S., Yamamura T., Takemiya S., Nagasaki H., Nishiyama K., Fukushima T., Hiki Y., Yamaguchi S., Kumada K., Shimada H., Mitomi T. & Makuuchi H. (2000) Feasibility of a novel weekday-on/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer. Cancer Chemotherapy and Pharmacology 46, 180-184.
61. Simons S., Ringsdorf S., Braun M., Mey U.J., Schwindt P.F., Ko Y.D., Schmidt-Wolf I., Kuhn W. & Jaehde U. (2011) Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Supportive Care in Cancer 19, 1009-1018.
62. Singh B.N. & Malhotra B.K. (2004) Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clinical Pharmacokinetics 43, 1127-1156.
63. Sommers R.M., Miller K. & Berry D.L. (2012) Feasibility pilot medication adherence and knowledge in ambulatory patients with gastrointestinal cancer. Oncology Nursing Forum 39, E373-E379.
64. Spoelstra S.L., Given B.A., Given C.W., Grant M., Sikorskii A., You M. & Decker V. (2013) An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents. Cancer Nursing 36, 18-28.
65. Tarquinio C., Fisher G.N. & Gregoire A. (2000) La compliance chez des patients atteints par le VIH: validation d'une échelle française et mesure de variables psychosociales. RIPS/IRSP 13, 51-91. 2000, Presses Universitaires de Grenoble. Revue internationale de Psychologie Sociale 2000, No. 2.
66. Uematsu T., Nakashima M., Fujii M., Hamano K., Yasutomi M., Kodaira S., Kato T., Kotake K., Oka H. & Masuike T. (1996) Measurement of 5-fluorouracil in scalp hair: a possible index of patient observance with oral adjuvant chemotherapy. European Journal of Clinical Pharmacology 50, 109-113.